Kornimate/medical-research-clean huggingface dataset:
comparison of upper extremity functional performance in hemophilic and healthy children

Conditions: Hemophilia; Upper Extremity; Strength; Performance; Children

Summary: the goal of this observational study is to evaluate the functional performance of the upper extremity joints (scapula, shoulder, elbow, and wrist) in haemophilic children and compare muscle strength and adl limitations with healthy children.

this study aims to evaluate the upper extremity functional performance, muscle strength, and daily living activity levels of hemophilic children and compare them with healthy children. the goal is to determine the effects of hemophilia on these children and contribute to the development of appropriate rehabilitation strategies. parameters include explosive strength, isometric muscle strength, wrist grip strength, and functional exercise capacity. additionally, the adl-glittre pediatric version test and hemophilia joint health score (hjhs) will be used to assess joint health and gya performance. muscle strength is crucial for hemophilic children to perform daily activities, and the relationship between muscle strength and gya levels will be investigated. the project aims to guide the development of physiotherapy and rehabilitation strategies for hemophilic children and contribute to the literature by filling existing gaps, ultimately creating an important reference for healthcare professionals and families.

Eligibility criteria:
inclusion criteria: * diagnosed with hemophilia a or b * receiving prophylaxis treatment (a routine treatment) * negative for inhibitors at the time of enrollment exclusion criteria: * positive for inhibitors at the time of enrollment * acute elbow bleeding * history of acute muscle bleeding * history of surgery in any upper extremity joints * having undergone radionuclide synovectomy

Keywords: hemophilia muscle strength upper extremity
efficacy and safety of sub-tenon ranibizumab for recurrent pterygia

Conditions: Pterygium

Summary: ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.

ptergyia are chronic fibrovascular lesions of the ocular surface. this study is designed to look for a signal of efficacy when the lesions are in a phase of active vascular growth. this phase is most often caught in a newly recurring pterygia post-operatively. patients identified with actively growing lesions, will be offered local injections directly beneath the lesions. they will be examined for any adverse side effects and regression of the lesion.

Eligibility criteria:
inclusion criteria: patients with actively growing pterygia, either surgical recurrences, or non-surgical primary lesions. exclusion criteria: * pregnancy * history of cva * monocular patients * minors

Keywords: pterygium
impact of neoadjuvant chemotherapy on the peripheral blood immune phenotype in operable breast cancer

Conditions: Invasive Breast Carcinoma

Summary: this early phase i trial evaluates the impact of chemotherapy before surgery (neoadjuvant) on the peripheral blood immune phenotype in patients with operable breast cancer. collecting blood and information from patients with breast cancer may help to understand how the immune system influences response to treatment, and how the immune system reacts to breast cancer treatment.

primary objectives: i. to evaluate whether pre-neoadjuvant chemotherapy (nac) peripheral blood immune phenotypes (defined by mass cytometry) are associated with pathologic complete response (pcr) after neoadjuvant chemotherapy in patients with operable breast cancer. ii. to evaluate whether the baseline peripheral blood immune phenotype differs between patients with breast cancer and age-matched healthy controls. secondary objectives: i. to characterize changes in the baseline peripheral blood immune phenotype that arise as a consequence of neoadjuvant chemotherapy. ii. to create a biorepository of peripheral blood samples for future research in breast cancer, including circulating tumor deoxyribonucleic acid (ctdna), epigenetic and functional studies. exploratory objective: i. to evaluate differences in peripheral blood immune phenotype of patients with oligometastatic breast cancer compared to patients with stage i-iii breast cancer. outline: patients undergo blood sample collection at baseline (prior to first nac treatment), after taxane and prior to first dose of anthracycline/cyclophosphamide (a/c) (for patients receiving a taxane), end of nac, 1-4 weeks and 6 months post-surgery. patients also undergo tissue collection at 1-4 weeks and 6 months post-surgery. after completion of study treatment, patients are followed up every 6 months for up to 5 years.

Eligibility criteria:
inclusion criteria: * age \>= 18 years * histologically confirmed, operable, invasive breast cancer. note: patients with oligometastatic breast cancer (up to 3 isolated distant metastases) will be eligible after review and approval by principal investigator (pi) * recommended to receive neoadjuvant systemic treatment by their primary medical oncologist and planning to receive one of the regimens * provide written informed consent * willing to return to mayo clinic for breast cancer surgery * willingness to provide mandatory blood specimens for future research on breast cancer at mayo clinic exclusion criteria: * patients who have already initiated neoadjuvant chemotherapy for the current malignancy * inability to provide blood samples based on the judgement of the treating physician * inability to comply with the protocol * patient is pregnant or plans to become pregnant
determinants of balance recovery after stroke - retrospective study

Conditions: Stroke

Summary: retrospective cohort study of consecutive patients investigated in a neurorehabilitation ward after a first hemispheric stroke. postural and gait disorders in relation to referential of verticality have been analyzed in routine care.

300 consecutive patients, admitted in our department for neurorehabilitation after a first hemispherical stroke, have been enrolled retrospectively. during their hospitalisation, all patients have been routinely evaluated with clinical scales, evaluating motor and cognitive deficits. postural and visual vertical (vv) assessments have been performed 1 to 4 times during in-patient-stay. the objective was to analyse the determinants of balance recovery after stroke, in particular the impact of wrong referential of verticality. data collection was performed by means of medical records. observation period covered from january 2012 to february 2018.

Eligibility criteria:
inclusion criteria: first hemispheric stroke patient non-opposed to inclusion exclusion criteria: history of neurological disorders interfering with balance history of vestibularly disorders interfering with balance unstable medical conditions history of cognitive disorders

Keywords: lateropulsion pusher syndrome posture balance pass verticality perception gait
a multicenter prospective study of risk factors in progressive pulmonary fibrosis

Conditions: Interstitial Lung Disease

Summary: the goal of this observational study is to learn about risk of progressive pulmonary fibrosis (ppf). the main questions it aims to answer are: * risk factors of ppf * prevalence of ppf * mortality of ppf patients with interstitial lung disease (ild) of known or unknown etiology other than ipf who has radiological evidence of pulmonary fibrosis will enroll in this study. * all participants will have baseline investigations at the first visit having provided informed consent. * at the first visit, baseline characteristics will be collected including demographics, medical history, smoking history, complications and medication use. 50 ml of blood will be obtained. high resolution computed tomography (hrct), full lung function tests and a 6 min walk test will be performed. * further visits at 6 months and 12 months will include further 50 ml blood sampling. hrct, full lung function tests and a 6 min walk test will be repeated.


Eligibility criteria:
inclusion criteria: * 18-80 years old * agree and sign the informed consent form * interstitial lung disease patients with imaging features of pulmonary fibrosis exclusion criteria: * patients with idiopathic pulmonary fibrosis (ipf) * pregnant or lactating women * mental illness or cognitive impairment * participating in other clinical studies * unable to sign informed consent form

Keywords: progressive pulmonary fibrosis
perioperative palliative care surrounding cancer surgery for patients & their family members

Conditions: Gastrointestinal Cancer

Summary: the study goal is to compare surgeon-palliative care team co-management, versus surgeon alone management, of patients and family members preparing for major upper gastrointestinal cancer surgery. the study also aims to explore, using qualitative methods, the impact of surgeon-palliative care team co-management versus surgeon alone management on the perioperative care experience for patients, family members, surgeons, and palliative care clinicians.

the components of surgeon palliative care team co management practices will include time, education, assessments, and multi disciplinary (team) element. 1. time; at least 60 minutes/month (per patient and caregiver preference) devoted to palliative care treatments for the patient and family 2. education - patients and family members, per their desires and wishes, are counseled and educated about their disease, including self-management of symptoms, prognosis, and treatment options 3. assessment - formal assessment of symptoms including pain, dyspnea, constipation/diarrhea, anxiety/depression, fatigue, and nausea. edmonton symptom score33 will be used as a formal assessment. 4. multi-disciplinary - management must be multi disciplinary with access to a multi-disciplinary palliative care team composed of nurse, physician, social worker, pharmacist, and/or chaplain team members.

Eligibility criteria:
inclusion criteria: * 18 years of age and must be able to give informed consent. * diagnosed with pancreatic cancer or hepatocellular cancer or esophageal cancer or gastric cancer and/or cholangio carcinomas * non emergent, upper gastrointestinal cancer related surgery with a goal of primary resection of the tumor- optimal surgical goal is cure, not merely disease palliation. * one companion per patient will be allowed to participate. in addition, to being identified by the patient at being a key caregiver throughout the surgery period, these companions must be able to give informed consent and at least 18 years of age. exclusion criteria: * no previous involvement of palliative care providers in their care course

Keywords: pancreatic cancer hepatocellular cancer esophageal cancer gastric cancer cholangio carcinomas
intracerebral gene therapy for children with early onset forms of metachromatic leukodystrophy

Conditions: Metachromatic Leukodystrophy

Summary: the objective of this open-label, single arm, monocentric, phase i/ii clinical study is to assess safety and efficacy of arsa gene transfer in the brain of children affected with early onset forms of metachromatic leukodystrophy (mld). for this purpose, an adeno-associated virus serotype rh.10 (aavrh.10) vector will be used to transfer the arsa cdna coding for arylsulfatase a (arsa) enzyme into the brain of children. five patients with early onset form of mld, age ranging from 6 months to 4 years, will be included in this protocol and will be followed during 24 months. patients will be selected at presymptomatic or early stage of their disease, following clinical, neuropsychological and brain imaging criteria. twelve simultaneous injections of the investigational medicinal product will be performed in the white matter of both brain hemispheres, through 6 image-guided tracks, with 2 deposits per track. a low dose (1x10exp12 vg total) will be administered to the first 2 patients, while the last 3 will receive a higher dose (4x10exp12 vg total). safety and efficiency will be evaluated based on clinical, neuropsychological, radiological, electrophysiological and biological parameters.


Eligibility criteria:
inclusion criteria: * boys or girls with an early onset form of mld. * age between 6 months and 5 years, inclusive * diagnostic of mld based on the measurement of arsa activity in leukocytes and the accumulation of sulfatides in urine, along with normal activity of at least one other sulfatase * informed consent signed up and willingness for monitoring 2 years after treatment. * normal values for standard laboratory tests exclusion criteria: * absence of arsa protein by immunocytochemistry and/or elisa * gestational age \<32 weeks of amenorrhoea and age \< 1 year * brain atrophy with a subdural space \> 10 mm in the frontal region * performance iq\<50 at wppsi-iii or cognitive function \< 3rd percentile at the bayley's test of infant development * if age \> 16 months at inclusion, inability to walk few steps alone or inability to walk few steps with support on one side along with inability to stand up alone * impossibility for anesthesia * malignancy, cardiac malformation, liver dysfunction, or renal dysfunction * neurological disorder, except benign, not related to mld. * any other clinically significant untreated co-morbid medical condition as determined by the clinical investigator, including cardiac, pulmonary or kidney disease. * mri impossibility * evoked potential impossibility * participation to another therapeutic clinical trial for mld. * unaffiliated to any french or any other national health insurance.

Keywords: brain gene therapy adeno associated vector lysosomal sotage diseases leukodystrophies
quality of anticoagulation with warfarin in patient with atrial fibrillation for secondary stroke prevention in korea

Conditions: Atrial Fibrillation; Stroke

Summary: the current study aims to assess the quality of anticoagulation with warfarin in real world practice of secondary stroke prevention in korean patients with atrial fibrillation (af) and to explore predictors for poor international normalized range (inr) control.

* to assess the quality of anticoagulation with warfarin in real world practice of korea for secondary stroke prevention in patients with af-related cardioembolic (ce) stroke 1) who initiated warfarin therapy and treatment at least for more than 7 days of warfarin adjustment period (warfarin-initiated cohort), and 2) who initiated and maintained warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period (long-term warfarin-treated cohort). * to explore predictors for poor inr control.

Eligibility criteria:
inclusion criteria: inclusion criteria for the warfarin-initiated cohort 1. admission due to af-related ischemic stroke 2. initiation of warfarin therapy and treatment at least for more than 7 days of warfarin adjustment period 3. for ttr calculation, available consecutive inr values ≥3 after the 7 days of warfarin adjustment inclusion criteria for the long-term warfarin-treated cohort 1. admission due to af-related ischemic stroke 2. long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period 3. for ttr calculation, available consecutive inr values ≥3 after the 7 days of warfarin adjustment 4. ttr evaluable days ≥ 90 days exclusion criteria: 1. af with mechanical valve 2. enrollment in anticoagulation randomized clinical trial 3. enrollment in studies affecting the target inr range.

Keywords: wafarin cardioembolic (ce) stroke ischemic stroke
a double-blind study of krn321 for the treatment of anemia in cancer patients

Conditions: Anemia

Summary: to compare the effectiveness of krn321 to placebo in the treatment of anemia in cancer patients receiving multi cycle platinum-containing chemotherapy


Eligibility criteria:
inclusion criteria: * patients diagnosed as lung or gynecological cancer * patients receiving platinum containing chemotherapy * written informed consent * hemoglobin concentration less than 11 d/dl at enrollment * life expectancy of more than 4 months exclusion criteria: * hemolysis, gastrointestinal bleeding, postoperative bleeding * iron deficiency * megaloblastic anemia * any primary hematological disorder that could cause anemia * received \> 2 rbc transfusions with 4 weeks or any rbc transfusion within 2 weeks before randomization * prior treatment with krn321 * received erythropoetin therapy within 8 weeks before treatment

Keywords: darbepoetin alfa anemia cancer patients platinum containing chemotherapy
comparison of two different antiplatelet preparations for an unruptured intracranial aneurysm

Conditions: Aneurysm, Cerebral; Endovascular Procedures

Summary: perform a randomized comparison study of dual-antiplatelet (aspirin, prasugrel) and triple-antiplatelet (aspirin, clopidogrel, and cilostazol) preparation using p2y12 assay in patients with high on-treatment platelet reactivity undergoing stent-assisted coil embolization for an unruptured intracranial aneurysm

comparison between dual-antiplatelet and triple-platelet preparation

Eligibility criteria:
inclusion criteria: * patients with clopidogrel resistance (greater than 220 p2y12 reaction units using verifynow) * patients with unruptured intracranial aneurysms * patients over 20 years old * patients who can communicate with each other * patients who agreed to this study (with informed consent) exclusion criteria: * patients with recurrent aneurysms after coiling or clipping * patients with allergic reaction to antiplatelets * patients with high risks of hemorrhage * patients with coagulopathy * patients with thrombocytopenia (\<100,000/mm3) * patients with liver disease (\> 100 of aspartate aminotransferase or alanine aminotransferase) * patients with renal disease (\> 2mg/dl of serum creatinine) * patients with uncontrolled heart failure or angina * patients with malignant tumor * pregnant patients * patients with past history that may associated with headache, including subarachnoid hemorrhage, head trauma, intracerebral hemorrhage, trigeminal neuralgia, arteriovenous malformation, brain tumor) * patients who are determined to be disqualified by researchers

Keywords: antiplatelet preparation cerebral aneurysm coil embolization
the effect of iabp early insertion on mortality in post cardiac arrest patients with acute coronary syndrome

Conditions: Post-Cardiac Arrest Syndrome

Summary: the prevalence of cardiac arrests is still high worldwide. despite the return of spontaneous circulation (rosc), mortality and morbidity in post cardiac arrest patients is reported high. comprehensive management is essential in treating patients with post cardiac arrest syndrome. adequate circulatory stability is achieved with fluid therapy, vasoactive drug therapy, and consideration of mechanical support. intra-aortic ballon pump (iabp) is one of the most feasible and available mechanical support in developing countries including indonesia. there are several benefits of iabp reported in acute myocardial infarction complicated with cardiogenic shock. nevertheless, the iabp-shock ii study revealed contradictive result which is iabp support was not improving mortality in acute myocardial infarction complicated with cardiogenic shock after revascularization. other study, korean acute myocardial infarction registry (kamir), also reported no benefits of iabp support in cardiogenic shock patients. but, the study the investigators mentioned earlier is a registry study, attributed to selection bias and several confounding factors resulting mismatch in population. there are no consideration to iabp time of initiation and duration of use in both studies. the investigator is aiming to prove the early insertion of iabp to a better outcome compared with the absence of early iabp. the objective of the study is to assess mortality in post cardiac arrest syndrome patients with early insertion of iabp support. a total of 102 subjects will be enrolled in this study, divided into iabp and non-iabp group. the primary outcome is in-hopital-mortality, and various indicators in the pathomechanisme of post cardiac arrest syndrome will be measured in 30 minutes and 6 hours after rosc. effective lactate clearance, il-6, beclin-1, caspase-3, a-vo2 diff, and scvo2, cardiac output, vti, tapse and ejection fraction will be measured and analized between the two groups.


Eligibility criteria:
inclusion criteria: 1. age greater than 18 and less than 75 years. 2. post cardiac arrest syndrome patients with decreased level of consciousness (cerebral performance categories (cpc) more than 1) and hypotension (systolic blood pressure less than 100) 3. experiencing successful cardiac rescucitation following cardiac arrest exclusion criteria: 1. history of stroke (based on interview) 2. unequal pupil 3. previous use of iabp 4. aorta regurgitation 5. brugada syndrome and congenital long qt drop-out criteria: 1. participants who died before iabp insertion 2. the family requests for a termination of treatment. 3. anemia caused by bleeding with hemoglobin decrement by \>3 gr/dl 4. ankle brachial index(abi) less than 0,8

Keywords: iabp post-cardiac arrest syndrome beclin-1 caspase-3 mortality
persantine: variation in response trial

Conditions: Coronary Artery Disease

Summary: the primary objective of this study is to understand why different people respond differently to the medication persantine. the effects of persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.

participants will receive three doses of persantine intravenously for the research study. before and after receiving the persantine doses, patients will have an echocardiogram and coronary artery blood flow will be measured. blood tests,measure the function of the adenosine transporter. in addition variations in the gene for the adenosine transporter will be evaluated.

Eligibility criteria:
inclusion criteria: * patients \> 21 years old * patient undergoing cardiac catheterization with planned ptca or with a significant coronary lesion of either the lad or circumflex exclusion criteria: * theophylline or oral persantine use in 24hrs * second or third degree av block, or sick sinus syndrome without a functioning pacemaker * active asthma or bronchospasm * patients with severe hepatic insufficiency * patients experiencing an acute transmural infarction at the time of the index visit * conditions that are known to affect resistive vessel function or myocardial flow
the effects of caffeine on vestibular evoked myogenic potentials in healthy subjects

Conditions: Healthy Subjects

Summary: the principal aim of this study is to evaluate the presence of changes in cervical vestibular evoked myogenic potentials (vempc) after acute intake of caffeine in healthy subjects. secondarily, it wants to standardize normal values exam vempc in otorhinolaryngology service of the hospital.


Eligibility criteria:
inclusion criteria: * healthy subjects exclusion criteria: * hearing impairment * caffeine abuse 24 hours before the test * medication remains * hypertension, dyslipidemia, diabetes mellitus or sleep disorders.

Keywords: caffeine vestibular evoked myogenic potentials dizziness vertigo tinnitus